Details of the Drug

General Information of Drug (ID: DMR0TYK)

Drug Name
Fosdenopterin
Synonyms CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec
Indication
Disease Entry ICD 11 Status REF
Molybdenum cofactor deficiency 5B5K.A Approved [1]
Encephalopathy 8E47 Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 363.22
Topological Polar Surface Area (xlogp) -4
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 7
Hydrogen Bond Acceptor Count (hbondacc) 11
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 5960 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 2800 mcg/L [3]
Clearance
The total body clearance of drug is 167-195 mL/h/kg [3]
Elimination
Approximately 40% of drug is eliminated via renal clearance [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.2 - 1.7 hours [3]
Metabolism
The drug is metabolized via the non-enzymatic degradation into Compound Z [3]
Vd
The volume of distribution (Vd) of drug is 0.3 L/kg [3]
Chemical Identifiers
Formula
C10H14N5O8P
IUPAC Name
(1R,10R,12S,17R)-5-amino-11,11,14-trihydroxy-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),4-dien-7-one
Canonical SMILES
C1[C@@H]2[C@@H](C([C@H]3[C@@H](O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O
InChI
InChI=1S/C10H14N5O8P/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16)/t2-,4-,5+,8-/m1/s1
InChIKey
CZAKJJUNKNPTTO-AJFJRRQVSA-N
Cross-matching ID
PubChem CID
135463437
ChEBI ID
CHEBI:60210
CAS Number
150829-29-1
DrugBank ID
DB16628
TTD ID
D07GTW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Xanthine dehydrogenase/oxidase (XDH) TT7RJY8 XDH_HUMAN Cofactor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2 ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health.
3 FDA Approved Drug Products: Nulibry (fosdenopterin) for intravenous injection
4 Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
5 Clinical pipeline report, company report or official report of Takeda (2009).
6 Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
7 Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
8 Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
9 QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
10 Clinical pipeline report, company report or official report of Teijin Pharma.
11 Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
12 An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.